XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 92.31

Change

0.00 (0.00)%

Market Cap

N/A

Volume

7.53M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-09 )

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

N/A

USD 0.04B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.50% 62% D 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.50% 62% D 84% B
Trailing 12 Months  
Capital Gain 2.03% 52% F 45% F
Dividend Return 0.14% 19% F 1% F
Total Return 2.18% 48% F 31% F
Trailing 5 Years  
Capital Gain -2.66% 24% F 46% F
Dividend Return 0.49% 26% F 1% F
Total Return -2.16% 19% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -1.36% 19% F 26% F
Dividend Return -1.28% 14% F 15% F
Total Return 0.08% 26% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 31.99% 19% F 33% F
Risk Adjusted Return -4.02% 19% F 18% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.